Stockreport

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to ini [Read more]